Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.18 +1.7%	$1.21	$0.86 ▼ $3.78	$257.38M	0.35	5.51 million shs	8.12 million shs
CRMD CorMedix	$14.35 +1.5%	$12.30	$5.31 ▼ $17.43	$1.06B	1.71	3.51 million shs	4.16 million shs
PRAX Praxis Precision Medicines	$45.99 -2.0%	$49.11	$26.70 ▼ $91.83	$987.47M	2.62	526,693 shs	195,796 shs
SYRE Spyre Therapeutics	$16.72 -2.5%	$16.26	$10.91 ▼ $40.26	$1.04B	2.82	481,175 shs	298,692 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	+9.43%	-21.09%	-1.69%	-56.72%
CRMD CorMedix	+1.07%	+4.59%	+18.03%	+15.71%	+129.17%
PRAX Praxis Precision Medicines	-2.05%	+3.69%	-15.69%	+22.03%	-12.33%
SYRE Spyre Therapeutics	+0.47%	+4.83%	+0.94%	+10.23%	-38.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	2.8627 of 5 stars	3.4	3.0	2.5	2.5	0.6
CRMD CorMedix	2.7133 of 5 stars	3.4	1.0	3.8	0.0	1.9
PRAX Praxis Precision Medicines	1.6892 of 5 stars	3.4	1.0	2.7	1.7	0.0
SYRE Spyre Therapeutics	3.0852 of 5 stars	3.6	2.0	3.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.75	Moderate Buy	$8.44	612.61% Upside
CRMD CorMedix	2.86	Moderate Buy	$17.33	21.30% Upside
PRAX Praxis Precision Medicines	2.75	Moderate Buy	$85.88	87.45% Upside
SYRE Spyre Therapeutics	3.29	Buy	$53.40	218.58% Upside

Current Analyst Ratings Breakdown

Latest ALLO, SYRE, PRAX, and CRMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $17.00
8/6/2025	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
8/5/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $115.00
8/4/2025	ALLO Allogene Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/4/2025	ALLO Allogene Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
7/29/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
7/18/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00
7/8/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$97.00 ➝ $115.00
6/30/2025	CRMD CorMedix	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/30/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/30/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	13,146.39	N/A	N/A	$1.55 per share	0.76
CRMD CorMedix	$43.47M	24.54	N/A	N/A	$2.96 per share	4.83
PRAX Praxis Precision Medicines	$8.55M	112.79	N/A	N/A	$19.21 per share	2.38
SYRE Spyre Therapeutics	$890K	1,137.56	N/A	N/A	$4.97 per share	3.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.11	N/A	N/A	N/A	N/A	-55.99%	-42.75%	11/6/2025 (Estimated)
CRMD CorMedix	-$17.93M	$0.75	18.97	15.20	N/A	42.11%	42.73%	34.19%	10/29/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$12.29	N/A	N/A	N/A	-2,137.48%	-60.07%	-54.84%	11/5/2025 (Estimated)
SYRE Spyre Therapeutics	-$208.02M	-$3.40	N/A	N/A	N/A	N/A	-71.30%	-38.69%	11/6/2025 (Estimated)

Latest ALLO, SYRE, PRAX, and CRMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALLO Allogene Therapeutics	-$0.28	-$0.23	+$0.05	-$0.23	N/A	N/A
8/7/2025	Q2 2025	CRMD CorMedix	$0.20	$0.28	+$0.08	$0.28	$29.88 million	$39.74 million
8/5/2025	Q2 2025	SYRE Spyre Therapeutics	-$0.73	-$0.49	+$0.24	-$0.49	N/A	N/A
8/4/2025	Q2 2025 & Study Result	PRAX Praxis Precision Medicines	-$3.40	-$3.31	+$0.09	-$3.31	$0.15 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	8.92	8.92
CRMD CorMedix	N/A	7.82	7.52
PRAX Praxis Precision Medicines	N/A	6.31	6.31
SYRE Spyre Therapeutics	N/A	6.49	6.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
CRMD CorMedix	34.18%
PRAX Praxis Precision Medicines	67.84%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
CRMD CorMedix	5.30%
PRAX Praxis Precision Medicines	2.70%
SYRE Spyre Therapeutics	15.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	221.88 million	192.59 million	Optionable
CRMD CorMedix	30	74.65 million	70.69 million	Optionable
PRAX Praxis Precision Medicines	110	21.05 million	20.48 million	Optionable
SYRE Spyre Therapeutics	73	60.40 million	51.08 million	Optionable

ALLO, SYRE, PRAX, and CRMD Headlines

Recent News About These Companies

Affinity Asset Advisors LLC Decreases Holdings in Spyre Therapeutics, Inc. $SYRE

August 28 at 9:02 AM | marketbeat.com

Vanguard Group Inc. Buys 51,794 Shares of Spyre Therapeutics, Inc. $SYRE

August 28 at 3:12 AM | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Wall Street Zen to "Hold" Rating

August 25 at 3:55 AM | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Trading Up 8.5% - Here's Why

August 15, 2025 | marketbeat.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from Brokerages

August 12, 2025 | marketbeat.com

XTX Topco Ltd Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

August 9, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Receives "Outperform" Rating from Wedbush

August 7, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPS

August 6, 2025 | marketbeat.com

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 5, 2025 | globenewswire.com

TD Asset Management Inc Has $361,000 Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

August 5, 2025 | marketbeat.com

Jefferies Financial Group Inc. Acquires 31,900 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

August 2, 2025 | marketbeat.com

Spyre Therapeutics Announces Grants of Inducement Awards

August 1, 2025 | globenewswire.com

Spyre Therapeutics (SYRE) Projected to Post Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Victory Capital Management Inc. Sells 16,230 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

July 28, 2025 | marketbeat.com

Here's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn Situation

July 16, 2025 | finance.yahoo.com

SYRE - Spyre Therapeutics Inc Trailing Returns - Morningstar

July 4, 2025 | morningstar.comM

Spyre Therapeutics Announces Grants of Inducement Awards

July 3, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)

June 20, 2025 | theglobeandmail.com

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward

June 18, 2025 | seekingalpha.com

Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development ...

June 17, 2025 | finanznachrichten.de

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

June 17, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALLO, SYRE, PRAX, and CRMD Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.18 +0.02 (+1.72%)

Closing price 04:00 PM Eastern

Extended Trading

$1.20 +0.02 (+1.69%)

As of 07:13 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

CorMedix NASDAQ:CRMD

$14.35 +0.21 (+1.49%)

Closing price 04:00 PM Eastern

Extended Trading

$14.32 -0.03 (-0.21%)

As of 07:59 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Praxis Precision Medicines NASDAQ:PRAX

$45.99 -0.93 (-1.98%)

Closing price 04:00 PM Eastern

Extended Trading

$46.02 +0.02 (+0.05%)

As of 05:36 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Spyre Therapeutics NASDAQ:SYRE

$16.72 -0.42 (-2.45%)

Closing price 04:00 PM Eastern

Extended Trading

$16.65 -0.07 (-0.42%)

As of 04:25 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time